您所在位置:首页 > 研究生教育 > 导师介绍 > 药剂学
黄永焯

姓名:黄永焯 性别: 职称:研究员 学历:博士 电话:0760-85286866 电子邮件:yzhuang@mail.shcnc.ac.cn 职务:课题组长 通讯地址:广东翠亨新区中瑞(欧)工业园健康医药示范区1号楼

  • 个人简历

    教育经历
    2002.09 - 2005.07 浙江大学药学院
    1999.09 - 2002.07 广州中医药大学临床药理研究所
    1995.09 - 1999.07 广州中医药大学中药学院
    工作经历
    2020.07 - 至今   中国科学院药物创新研究院中山研究院
    2010.07 - 至今   中国科学院上海药物研究所
    2008.09 - 2010.06 University of Michigan, Senior Research Fellow
    2005.11 - 2008.08 University of Michigan, Research Fellow

    现任International Journal of Pharmaceutics 编辑,Nano Letters, Journal of Controlled Release 编委;中药新药与临床药理、中国现代应用药学、药学进展编委,Acta Pharmaceutica Sinica B、药学学报青年编委。任中国药学会药剂学专业委员会委员,中国药学会纳米药物专业委员会委员。

  • 研究领域

    1.靶向给药系统;
    2.透皮给药;
    3.难溶性药物给药技术。

  • 研究成果

    采用先进药物递送技术提高体内药物输送效率,并对其转运特性及机制进行了研究,着重考察了在耐药肿瘤治疗的应用。多药耐药已成为了肿瘤治疗最大的障碍之一,本课题组的研究聚焦于耐药肿瘤治疗的这一关键科学问题,通过靶向调控肿瘤微环境的递药策略及治疗策略,致力于研究肿瘤相关巨噬细胞调控与肿瘤耐药(化疗耐药、分子靶向治疗耐药及免疫耐药)。

  • 代表性论著(*:通讯作者)

    1. Fang YF#, He Y#, Wu CH, Zhang M, Gu ZY, Zhang JX, Asrorov A.M., Xu Q*, Huang YZ*. Magnetism-Mediated Targeting Hyperthermia-Immunotherapy in “Cold” Tumor with CSF1R Inhibitor, Theranostics 2021, DOI: 10.7150/thno.57511

    2. Wu AH, Chen YZ, Wang HR, Chang Y, Zhang M, Zhao PF, Tang YS, Xu Q*, Zhu ZZ, Huang YZ*. Genetically-Engineered “All-in-One” Vaccine Platform for Cancer Immunotherapy. Acta Pharmaceutica Sinica B 2021, online

    3. Asrorov AM, Gu ZY, Li F*, Liu LY, Huang YZ*, Biomimetic Camouflage Delivery Strategies for Cancer Therapy. Nanoscale 2021, online

    4. He ZD, Zhang M, Wang YH, He Y, Wang HR, Chen BF, Tu B, Zhu SQ, Huang YZ*. Anti-PD-L1 mediating tumor-targeted codelivery of liposomal irinotecan/JQ1 for chemo-immunotherapy. Acta Pharmacologica Sinica. 2021. doi: 10.1038/s41401-020-00570-8

    5. Zhao P, Zhang J, Wu A, Zhang M, Zhao Y, Tang Y, Wang B, Chen T, Li F, Zhao Q*, Huang YZ*. Biomimetic codelivery overcomes osimertinib-resistant NSCLC and brain metastasis via macrophage-mediated innate immunity. Journal of Control Release 2021, 329:1249-1261

    6. Zhen ZN, Zhang JX, Jiang JZ, He Y, Zhang WY, Mo XP, Kang XJ, Xu Q*, Wang B, Huang YZ*. Remodeling Tumor Immune Microenvironment (TIME) for Glioma Therapy Using Multi-Targeting Liposomal Codelivery. Journal for ImmunoTherapy of Cancer 2020: e000207

    7. Zhao YG, Yang YT, Zhang JX, Wang R, Cheng BY, Kalambhe D, Wang YS, Gu ZY, Chen DY*, Wang B*, Huang YZ*. Lactoferrin-mediated macrophage targeting delivery and patchouli alcohol-based therapeutic strategy for inflammatory bowel diseases. Acta Pharmaceutica Sinica B 2020: 1966-1976

    8. Chen BF, Gao A, Tu B, Wang YH, Yu XL, Wang YS, Xiu YF, Wang B, Wan YK, Huang YZ* Metabolic modulation via mTOR pathway and anti-angiogenesis remodels tumor microenvironment using PD-L1-targeting codelivery. Biomaterials 2020, 255:120187

    9. Yin WM, Zhao YG, Kang XJ, Zhao PF, Fu X, Mo XP, Wang YH, Wan YK, Huang YZ*. BBB-penetrating codelivery liposomes treat brain metastasis of non-small cell lung cancer with EGFRT790M mutation. Theranostics 2020, 10(14): 6122

    10. Tu B, He Y, Chen B, Wang Y, Gao Y, Shi M, Liu T, Asrorov AM, Huang YZ*. Deformable liposomal codelivery of vorinostat and simvastatin promotes antitumor responses through remodeling tumor microenvironment. Biomaterial Science 2020, 8:7166-7176

    11. Wang HR, Huang YZ*. Combination Therapy Based on Nano Codelivery for Overcoming Cancer Drug Resistance. Medicine in Drug Discovery 2020: 100024

    12. Chang Y, Jiang J, Chen W, Yang W, Chen L, Chen P, Shen J, Qian S, Zhou T, Wu LF, Hong L, Huang YZ*, Li F*. Biomimetic metal-organic nanoparticles prepared with a 3D-printed microfluidic device as a novel formulation for disulfiram-based therapy against breast cancer. Applied Materials Today 2020, 18: 100492

    13. Zhang JX, Zhao YG, Hou T, Zeng H, Kalambhe C, Wang B*, Shen X, Huang YZ*. Macrophage-based nanotherapeutic strategies in ulcerative colitis. Journal of Controlled Release 2020, 320:363 (Back cover)

    14. Tu B, Zhang M*, Liu T, Huang YZ*. Nanotechnology-Based Histone Deacetylase Inhibitors for Cancer Therapy. Frontiers in Cell and Developmental Biology 2020, 8: 400

    15. Asrorov AM, Gu Z, Min KA, Shin MC*, Huang YZ* Advances on Tumor-Targeting Delivery of Cytotoxic Proteins. ACS Pharmacology & Translational Science 2020, 3(1): 107

    16. Ouyang X, Wang X, Kraatz HB, Ahmadi S, Gao J, Lv Y, Sun X*, Huang YZ*. A Trojan horse biomimetic delivery strategy using mesenchymal stem cells for PDT/PTT therapy against lung melanoma metastasis. Biomaterials Science 2020, 8: 1160